May 13, 2025
We are pleased to announce the launch of the innovative HIVEC (Hyperthermic Intravesical Chemotherapy) treatment at the University General Hospital of Larissa (PGNL)!
This development marks a significant milestone for oncology care in the region, as PGNL becomes the first center in Thessaly to offer this advanced therapeutic option.
HIVEC is a specialized and effective treatment for non-muscle invasive bladder cancer. The benefits for patients in Thessaly are considerable:
Access to advanced treatment locally: Patients no longer need to travel to other centers in Greece, significantly reducing both inconvenience and associated costs.
Lower recurrence rates: HIVEC has demonstrated a reduced risk of cancer recurrence compared to other intravesical therapies.
Improved quality of life: Preserving the bladder offers substantial quality-of-life benefits for patients.
We would like to extend our sincere gratitude to Professor Vasilios Tzortzis, Head of the Urology Department at PGNL, for his vital contribution and unwavering commitment to introducing this life-enhancing therapy. His foresight and dedication to delivering high-quality care to the patients of Thessaly are truly commendable.
Special thanks also go to his esteemed colleagues, Dr. Mitrakas and Dr. Dimitropoulos, for their valuable support and contribution.
We wish continued success to the medical and nursing staff of PGNL in the implementation of this treatment and remain hopeful that it will bring relief and renewed hope to many patients across the region.
